LONDON--(BUSINESS WIRE)--Sinophi Healthcare Ltd, the China hospital investment and management company, announces today that during the State Visit to the UK by China’s President Xi Jinping, the company has signed seven hospital deals in China worth £800 million. These are focused on proton therapy to treat cancer. The seven hospitals include one oncology hospital with a proton centre and one maternity hospital in the city of Huai’an, as well as five Sinophi Proton Centres in Beijing, Changchun, Fuzhou, Luoyang and Nanjing with a combined total investment in building, infrastructure, operation and costs of £800 million.
Following a meeting with China’s President Xi Jinping and UK Prime Minister David Cameron, a signing ceremony was held in London witnessed by the UK Minister of State for Life Sciences Mr George Freeman MP. Sinophi Healthcare’s Dr Hanif Kanji, Chief Executive, and Professor Zhao GuoQing, President of the China-Japan Union Hospital of Jilin University signed a deal to build a Sinophi Proton Centre at the hospital. It was also announced that a purchase order was signed with Advanced Oncotherapy plc for a LIGHT proton therapy machine for the facility. The China-Japan Union Hospital is located in Changchun, Jilin Province and is one of the largest hospitals in NE China with 3,328 beds.
At the signing ceremony Sinophi announced Framework Agreements to build four other Sinophi Proton Centres. These have been signed with Beijing Shijitan Hospital affiliated with Capital Medical University in Beijing; Nanjing Drum Tower Hospital affiliated with Nanjing University Medical School in Nanjing, Jiangsu Province; Luoyang Central Hospital affiliated to Zhengzhou University, in Luoyang, Henan Province and Fuzhou City Health Bureau in Fuzhou, Fujian Province.
These Sinophi Proton Centres in China bring together the best of Chinese oncology treatment and expertise with the advanced proton therapy technology of Advanced Oncotherapy plc of the UK.
China currently has one proton centre in Shanghai. The combined population of the six Chinese cities where the Sinophi Proton Centres will be located is over 60 million people, with patients also expected to come from neighbouring cities and provinces (Jiangsu, Henan, Hebei, Fujian and Jilin provinces) with another 250 million people.
The two announced Sinophi Healthcare hospital deals in the city of Huai'an are for an oncology hospital with a proton centre and for a maternity hospital. These will be built in partnership with the Huai’an First People’s Hospital (3,000 beds) and with Huai Yin Hospital (1,000 beds). Sinophi China Hospital Holdings Limited, a company invested by Sinophi Healthcare, Morgan Stanley Private Equity Asia, Sihuan Pharmaceutical and Euromax will invest in the two hospitals. Sinophi China Hospitals Holdings has already invested in Huai Yin Hospital.
Commenting on the signings, Dr Hanif Kanji, CEO of Sinophi Healthcare Ltd said: “The UK and China have many shared challenges dealing with cancer. Our Sinophi Proton Centres in six of China’s leading cities will expand to more Chinese cities in future. We support the objectives of the Chinese Government’s healthcare reform programme by making proton treatment widely available at reduced cost, saving lives and improving the quality of life of cancer patients. The next generation proton therapy technology of Advanced Oncotherapy plc, developed at their ADAM subsidiary (a spin-off from CERN in Geneva), will enable many more people to benefit in their treatment from the greater accuracy and fewer side effects of proton therapy compared to X-ray radiotherapy."
About Sinophi Healthcare (www.sinophi.com)
Sinophi Healthcare is a UK company which invests in and manages hospitals in China, focused on public general hospitals and selected specialty and super specialty hospitals. Sinophi works in partnership with hospitals in China’s rapidly growing urban areas to deliver improvements in the delivery of healthcare. Sinophi brings to hospitals in China international hospital expertise and technology, building links with hospitals in the UK’s National Health Service system and partnerships with leading UK and international healthcare service and product partners.
